Drug intelligence / Profile preview

SVF-002

Development stage: Preclinical
Lead developer: SVF Vaccines
Modality: mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous, Intraarticular, Spinal, Subcutaneous, Local, Intramuscular

Overview

SVF-002 is a universal influenza vaccine candidate being developed by SVF Vaccines. The program utilizes a dual-platform approach, incorporating both DNA and mRNA vaccine technologies to elicit broad and durable protection against multiple strains of the influenza virus. By targeting conserved viral components, SVF-002 aims to provide a "universal" solution that could potentially provide protection against diverse seasonal and pandemic strains, reducing the need for annual vaccine updates. The vaccine is currently in the preclinical stage of development.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on SVF-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SVF-002.